Zacks Investment Research
Positive
6/23 9:21 PM
Biotech's Silent Resurgence (5-Year Base Breakout)
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
The Motley Fool
Positive
6/23 8:30 PM
2 High-Yield Dividend Stocks to Buy and Hold for a Decade
These healthcare leaders have encountered challenges in recent years. However, they are slowly improving their businesses, partly through innovation.
24/7 Wall Street
Positive
6/23 5:55 PM
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose
Reuters
Neutral
6/23 4:10 PM
China outpacing Europe in drug innovation and development, Pfizer executive says
China has pulled ahead of Europe in pharmaceutical innovation and drug development, a senior Pfizer executive said on Tuesday.
Zacks Investment Research
Positive
6/23 2:30 PM
Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.
Business Wire
Neutral
6/23 2:00 PM
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 4, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2026 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. In.
Reuters
Negative
6/22 8:43 PM
Pfizer's experimental drug misses main goal of lung cancer trial
Pfizer said on Monday its drug for a type of lung cancer missed the main goal of a late-stage trial.
Business Wire
Neutral
6/22 8:30 PM
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy. In the overall population, sigvo.
24/7 Wall Street
Neutral
6/22 8:02 PM
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry.
Market Watch
Positive
6/22 6:32 PM
Wall Street loves growth stocks — but these 10 ‘losers' are primed to win
Elon Musk's $1 trillion SpaceX prediction is probably wrong. Contrarian investors are buying these out-of-favor value plays instead.
52W Range
$23.11 - $28.75
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
